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Editorial
Continuous professional 
development: elevating thoracic 
oncology education in Europe
Thoracic oncology encompasses a broad spectrum 
of primary tumour entities originating from various 
pulmonary, tracheobronchial, pleural, mediastinal 
and chest wall tissues or distinct cell types within 
these compartments. Lung cancer represents by 
far the most frequent malignant tumour within 
the thoracic cavity, and is the most common type 
and largest killer among all cancers worldwide. 
Lung cancer leads mortality statistics in Europe, 
accounting for at least one fifth of all cancer-
related deaths [1]. In addition, lung cancer causes 
a significant burden of symptoms in a population of 
patients with high comorbidity, providing significant 
challenges to national healthcare systems in the 
European Union, with the highest overall costs 
among all cancer types [2–4]. Contrary to the 
general stigma applied to lung cancer patients, 
where they are often assumed to suffer from a 
self-inflicted disease, it is now estimated that 
up to 10–20% of lung cancer patients are never-
smokers [5, 6]. Even if numerically far lower, the 
remaining <5% of primary thoracic malignancies 
other than lung cancer challenge thoracic oncology 
specialists, as well general pulmonologists, often 
in daily practice, be they pleural mesotheliomas, 
thymic or neuroendocrine tumours, sarcomas or 
rare entities such as germ-cell tumours [7, 8].
Epoch-making progress has been made recently 
in thoracic oncology after decades of only minor 
improvements regarding prognosis. Nowadays, 
detailed molecular tumour profiling has led to 
personalised diagnostic–therapeutic sequences. 
In addition, immunotherapy is developing as the 
most exciting and fundamental turning point in the 
history of lung cancer treatment. In 2009, when 
this step-change in highly effective therapeutic 
approaches was not yet foreseeable, the European 
Respiratory Society (ERS) implemented the far-
sighted decision to create its own Thoracic Oncology 
Assembly. The first step of a detailed, forward-
looking action plan was launched in 2010 [9]. In 
subsequent years, the role of the pulmonologist 
as pilot and partner in thoracic oncology has been 
introduced by the American Thoracic Society and 
the ERS [10].
Against this background, the Thoracic Oncology 
Assembly has been able to create a basis for 
standard educational formats and activities in line 
with the overall ERS strategy over the last few years. 
Amongst other initiatives, particularly the HERMES 
(Harmonised Education in Respiratory Medicine 
for European Specialists) programme for Thoracic 
Oncology, this has provided a comprehensive 
template in the field and is recognised worldwide as a 
role model [11–13]. Given the currently hyperdynamic 
environment, the Thoracic Oncology Assembly 
now faces the fascinating opportunity to promote 
an adapted action plan. While scientific, diagnostic 
and therapeutic advances are evolving rapidly, the 
European routine care landscape in thoracic oncology 
is characterised by a vast heterogeneity in available 
resources as well as in responsible professionals. 
The field of systemic therapies for patients with 
thoracic malignancies is one clear example: in 
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about half of European countries, the involvement 
of pulmonologists in systemic therapy is essential, 
contrasting with a significant number of nations in 
which pulmonologists are neither specifically trained 
nor active in this area [14]. Scientific progress does 
not pay any attention to currently established core 
pneumological skills in thoracic oncology. Rather, 
it may be envisaged that endoscopic methods 
will become insignificant in the medium term 
through the ongoing evolution of sometimes 
co-equal noninvasive diagnostic measures, namely 
the increasing maturity of liquid biopsies [15]. 
The advent of high-quality data demonstrating 
mortality reduction with lung cancer screening 
poses a separate but enormous challenge in quality 
control, implementation and rational delivery of a 
programme, which may transform our approach to 
lung cancer. Thus, there is to date an inadequately 
addressed need for continuous professional 
development (CPD) among pulmonologists to 
keep pace with the revolutionary trends in thoracic 
oncology.
An innovative campaign towards 
a joint and vivid educational 
platform in thoracic oncology
The answer to these demanding challenges is 
firstly one of communication. Analogous to the 
ERS master plan for other respiratory disease 
areas, our present educational thoracic oncology 
platform will be transformed stepwise from a fixed 
masterpiece to a dynamically adapting up-to-date 
platform. This new and unique platform is meant to 
arouse true thirst for knowledge in both general and 
specialised clinicians, and furthermore, to enable 
realistic, targeted CPD tailored to personal needs 
and individual professional career stages.
This document highlights the essential steps 
from the development towards the aspired 
implementation of the new ERS educational 
programme in thoracic oncology, and provides 
insights into the underlying CPD syllabus, planned 
educational contents and formats as well as specific 
communication strategies.
From our mission to strengthen and improve 
the diagnosis and care of thoracic malignancies 
in Europe, we envisage an adaptive and evidence-
based CPD matrix based on multidisciplinary 
education. Our educational campaign seeks to cover 
the entire continuum of thoracic malignancy. We 
aim to provide attractive educational formats to 
all physicians and allied health professionals with 
an interest in thoracic oncology, independent of 
original discipline, grade of specialisation or current 
career status. Multidimensional collaboration 
within and outside the ERS is key to achieve these 
ambitious goals, namely by:
●● Horizontal linkage with other related ERS 
assemblies
●● Ensuring multiprofessionality and patient 
representation by incorporating allied 
respiratory professionals and the European Lung 
Foundation, respectively
●● Cooperation with other dedicated international 
partner societies in the field of thoracic oncology 
(i.e. the European Society of Radiology, the 
European Society of Thoracic Surgeons and the 
International Association for the Study of Lung 
Cancer)
●● Vertical liaison with respiratory societies and 
thoracic oncology services on the national and 
local levels, aiming to set up a harmonised 
framework of thoracic oncology education and 
its better implementation throughout Europe, 
both in countries with higher and lower financial 
capacities
To adequately meet the varying interests and 
expectations of the aforementioned targeted 
individuals, we will perform regular need 
assessments via surveys and other social media 
means, from which we will derive target group-
specific educational formats. Feedback loops will 
be used to improve the future quality of our CPD 
programme, including the involved faculty. Likewise, 
we will constantly track and appraise new scientific 
and political developments in the field of thoracic 
oncology in order to provide up-to-date and 
evidence-based professional development.
Contextual basis and 
educational formats
We will use our thoracic oncology CPD syllabus 
as the contextual basis of our educational 
programme. This recently developed catalogue 
stretches from carcinogenesis, through symptoms, 
imaging, multidisciplinary team care, systemic 
therapy and malignant pleural effusion, covering 
the thoracic oncology trajectory in 32 modules as 
shown in table 1. Each module has been created 
via a fixed route: design, creation, internal revision, 
adaptation, external revision and final adaptation. 
Each module will be maintained and regularly 
updated according to future developments by a 
faculty composed of early career members and 
senior scientific specialists in thoracic oncology.
The platform used to provide these thoracic 
oncology educational modules is a comprehensive 
and adaptive international learning hub with the 
application of new digital techniques provided by 
the ERS. We will apply new and well-established 
ERS educational formats, particularly the following.
●● Electronic learning: continuing medical 
education (CME) online modules and CME tests
●● ERS courses: skills and online
●● Online and printed publications: ERJ Open 
Research, the European Respiratory Review, 
Breathe and the ERS Monograph, with a 
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longer-term aim of introducing an ERS Handbook 
of Thoracic Oncology
●● Events: ERS International Congress, satellite 
meetings, research seminars, ERS Live and Best 
of ERS
●● Online blogs: ERS Respiratory Digest
●● Social media: quizzes
●● HERMES examinations
We will involve prestigious senior faculty and 
Europe’s top-tier thoracic oncology services, but 
also provide committed early career members 
with sufficient opportunities to participate in our 
educational formats, since the latter represent our 
future.
A general description of the named ERS 
educational formats can be found on the ERS 
website: https://www.ersnet.org/professional-
development/cpd/cpd-thoracic-oncology. An 
outline of our planned thoracic oncology-specific 
educational formats in 2019/2020 is depicted in 
table 2. The educational platform of our Thoracic 
Oncology Assembly, with regular updates, can be 
viewed on the ERS website as well.
Education recognition
We aim to gain education recognition in multiple 
ways. First, high quality of each module should 
be pursued; then, we aim to obtain international, 
Table 1 Module-based CPD training
Module 1 Carcinogenesis, immunology and defence mechanisms
Module 2 Tobacco: risk factors and epidemiology
Module 3 Indoor and outdoor pollution
Module 4 Respiratory hazards associated with occupational factors
Module 5 Asbestos-related diseases
Module 6 Lung cancer screening
Module 7 Signs and symptoms
Module 8 Imaging techniques
Module 9 Bronchoscopy
Module 10 Advanced endoscopy
Module 11 Thoracoscopy and pleural diagnostics
Module 12 Evaluation of patient fitness for diagnostics and therapy
Module 13 Pathology
Module 14 Multidisciplinary team and multidisciplinary team meeting
Module 15 Thoracic surgery
Module 16 Radiotherapy
Module 17 Systemic pharmacotherapy
Module 18 Immunotherapy
Module 19 Rehabilitation
Module 20 Smoking prevention and cessation
Module 21 Palliative care including treatment of tumour-related symptoms and complications
Module 22 Patient and family support
Module 23 Management of paraneoplastic syndromes
Module 24 Thromboembolic disease in thoracic oncology
Module 25 Thoracocentesis including chest tube and tunnelled indwelling pleural catheter
Module 26 Common side effects of systemic therapies and their management
Module 27 Common radiation-induced side effects and their management
Module 28 Solitary pulmonary nodules
Module 29 Malignant pleural mesothelioma
Module 30 Mediastinal tumours
Module 31 Common metastatic pulmonary tumours
Module 32 Malignant pleural effusion
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standardised quality certifications, such as CME. 
Such recognition is an important step in the 
implementation strategy and will strengthen the 
communication strategy, both of which are essential 
to reach out to as much as possible of the target 
audience. Similar to the successfully established 
sleep medicine programme [16], we strive to 
facilitate implementation of our educational 
initiative into existing national training programmes 
for thoracic oncology. This will allow recognition of 
elevating international standards in this important 
and rapidly changing field of respiratory medicine. 
It will also allow the certificate of completion of 
this CPD programme to be a quality-measuring 
instrument when employing respiratory physicians 
or researchers from abroad, and thus promote the 
transfer of knowledge inside Europe and beyond.
Communication
In an age of transition from analogue towards 
digital tools, a digital platform is essential to 
communicate with the target audience and the 
participants. The ERS already has an excellent 
basis for this activity to enhance participation 
and recognition of the thoracic oncology CPD 
programme. We envision stretching out from the 
ERS base to our international, national and local 
partners, seeking fruitful and cordial collaboration 
as well as avoidance of needless duplication of work. 
Together, we can use all digital and social media to 
deliver the message and the education itself. Using 
the available ERS communication channels, we can 
already be strong, but through partnership, we will 
be even stronger and more far reaching.
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